Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin's clinical durability

Samuel E. Blechman,Erik S. Wright

DOI: https://doi.org/10.1371/journal.ppat.1012422

IF: 7.464

2024-09-02

PLoS Pathogens

Abstract:Vancomycin has proven remarkably durable to resistance evolution by Staphylococcus aureus despite widespread treatment with vancomycin in the clinic. Only 16 cases of vancomycin-resistant S . aureus (VRSA) have been documented in the United States. It is thought that the failure of VRSA to spread is partly due to the fitness cost imposed by the vanA operon, which is the only known means of high-level resistance. Here, we show that the fitness cost of vanA -mediated resistance can be overcome through laboratory evolution of VRSA in the presence of vancomycin. Adaptation to vancomycin imposed a tradeoff such that fitness in the presence of vancomycin increased, while fitness in its absence decreased in evolved lineages. Comparing the genomes of vancomycin-exposed and vancomycin-unexposed lineages pinpointed the D-alanine:D-alanine ligase gene ( ddl ) as the target of loss-of-function mutations, which were associated with the observed fitness tradeoff. Vancomycin-exposed lineages exhibited vancomycin dependence and abnormal colony morphology in the absence of drug, which were associated with mutations in ddl . However, further evolution of vancomycin-exposed lineages in the absence of vancomycin enabled some evolved lineages to escape this fitness tradeoff. Many vancomycin-exposed lineages maintained resistance in the absence of vancomycin, unlike their ancestral VRSA strains. These results indicate that VRSA might be able to compensate for the fitness deficit associated with vanA -mediated resistance, which may pose a threat to the prolonged durability of vancomycin in the clinic. Our results also suggest vancomycin treatment should be immediately discontinued in patients after VRSA is identified to mitigate potential adaptations. The clinical utility of antibiotics is threatened by the potential evolution of resistance in the pathogen being targeted. Thus, we seek to understand why some antibiotics effectively evade the evolution of resistance. Vancomycin has remained one of the few effective antibiotics in the treatment of methicillin-resistant Staphylococcus aureus (MRSA), with few cases of vancomycin-resistant S . aureus (VRSA) being reported. However, the basis of vancomycin's durability and the ability of VRSA to further adapt to vancomycin in the laboratory has yet to be investigated. Herein, we describe the evolutionary trajectories of several laboratory-propagated VRSA strains. We show that VRSA can overcome the fitness cost imposed by vancomycin resistance, a result which threatens the long-term use of vancomycin in the clinic.

microbiology,virology,parasitology